Madrigal Pharmaceuticals, Inc. (MDGL) Reaches $107.00 After 8.00% Up Move; Newstar Financial (NEWS) Sentiment Is 1.75

January 14, 2018 - By wolcottdaily

The stock of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a huge mover today! The stock increased 8.26% or $8.16 during the last trading session, reaching $107. About 253,563 shares traded or 45.46% up from the average. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 7 months positive chart setup for the $1.50 billion company. It was reported on Jan, 14 by Barchart.com. We have $115.56 PT which if reached, will make NASDAQ:MDGL worth $119.84M more.

NewStar Financial, Inc. operates as a commercial finance firm in the United States. The company has market cap of $497.84 million. The firm operates through two divisions, Commercial Lending and Asset Management. It has a 25.01 P/E ratio. It provides senior secured cash flow loans, and second lien and unitranche loans to middle market companies for acquisitions, recapitalizations, and refinancing or other general corporate purposes; senior debt financing options, including revolving credit facilities, term loans, and other debt products secured by various business assets; and senior secured loans to larger middle market companies in healthcare, manufacturing and industrial, financial services, energy/chemical services, printing/publishing, consumer, retail and restaurants, and business and technology services industries.

Analysts await Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to report earnings on April, 2. They expect $-0.69 EPS, down 2.99% or $0.02 from last year’s $-0.67 per share. After $-0.68 actual EPS reported by Madrigal Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.47% negative EPS growth.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $1.50 billion. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

Capital Z Partners Management Llc holds 100% of its portfolio in NewStar Financial, Inc. for 4.04 million shares. Corsair Capital Llc owns 4.26 million shares or 22.72% of their US portfolio. Moreover, Second Curve Capital Llc has 6.33% invested in the company for 1.35 million shares. The New Jersey-based Selkirk Management Llc has invested 5.47% in the stock. Oaktop Capital Management Ii L.P., a New Jersey-based fund reported 2.26 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 wolcottdaily







Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: